Skip to main content

Healthcare- and pharma-economic models in support of the International Consortium for Personalised Medicine

Deliverables

Budget impact models

Budget impact models developed for the 3 case studies

Cost-effectiveness models

Costeffectiveness models developed for the 3 case studies

Recommendation on the refinement of the guidance developed in WP1

Recommendation on the refinement of the guidance developed in WP1

All models populated with input data from 3 EU Member States

All models populated with input data from 3 EU Member States

Report of the Stakeholder Conference

Report of the Stakeholder Conference

Guidance paper on health economic modelling of per-sonalised medicine

Guidance paper on health economic modelling of per-sonalised medicine

Checklist methodological quality

Checklist to assess the methodological quality of model-based economic evaluations of personalised medicine

financing and payment models

A set of appropriate financing and payment models for personalised medicine for different types of health care systems in EU

action plan

An action plan to adopt appropriate financing and payment models for personalised medicine across EU

Synthesis Report of virtual WS1 and 2

Synthesis Report of virtual WS1 and 2

Overview of major findings from interviews

Overview of major findings from interviews

Report of the WS2

Report of the WS2

"Report on ""The Benefits & Challenges"""

Report on The Benefits Challenges of Personalised Medicine for the European Social Models of Health Care

Workshop 1 report

Workshop 1 report

Searching for OpenAIRE data...

Publications

POSB75 What is the Net Added Value of Personalised Medicine? A Systematic Literature Review

Author(s): Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Isaac Corro-Ramos, László Szilberhorn, Tamás Zelei, Balázs Nagy, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth, Maureen Rutten-van Mölken
Published in: Value in Health, 2022
Publisher: ISPOR
DOI: 10.1016/j.jval.2021.11.348

105P Prognostic value of the NTRK fusion biomarker in the Netherlands

Author(s): Irene Santi, Heleen Vellekoop, Simone Huygens, Maureen Rutten-van Mölken, Matthijs Versteegh
Published in: Annals of Oncology, 2021, ISSN 1569-8041
Publisher: Elsevier
DOI: 10.1016/j.annonc.2021.08.385

Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2,022 UK patients

Author(s): Rositsa Koleva-Kolarova, James Buchanan, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen Rutten-van Molken, László Szilberhorn, Tamás Zelei, Balázs Nagy, Sarah Wordsworth, Apostolos Tsiachristas
Published in: BMC Cancer (SUBMITTED), 2023
Publisher: Springer

Financing and reimbursement models for personalised medicine: a review to identify current models and future options

Author(s): Rositsa Koleva-Kolarova, James Buchanan, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen Rutten-van Molken, László Szilberhorn, Tamás Zelei, Balázs Nagy, Sarah Wordsworth, Apostolos Tsiachristas
Published in: Applied Health Economics and Health Policy (ACCEPTED), 2022
Publisher: Springer

RE1 Financing and Reimbursement for Personalised Medicine - Are WE There YET?

Author(s): Rositsa Koleva-Kolarova, James Buchanan, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen Rutten-van Molken, László Szilberhorn, Tamás Zelei, Balázs Nagy, Sarah Wordsworth, Apostolos Tsiachristas
Published in: Value in Health, 2020
Publisher: ISPOR
DOI: 10.1016/j.jval.2020.08.2071

Systematic review of financing and reimbursement models for personalised medicine.

Author(s): Rositsa Koleva-Kolarova, Apostolos Tsiachristas, James Buchanan, Sarah Wordsworth
Published in: PROSPERO 2019 CRD42019146764, n/a, 2020, Page(s) n/a
Publisher: PROSPERO

Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients

Author(s): Apostolos Tsiachristas, Grant Vallance, Rositsa Koleva-Kolarova, Harriet Taylor, Luke Solomons, Giovanni Rizzo, Catherine Chaytor, Junel Miah, Sarah Wordsworth & A. Bassim Hassan
Published in: BMC cancer, 2022, ISSN 1471-2407
Publisher: BioMed Central
DOI: 10.1186/s12885-022-09576-3

Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options

Author(s): Rositsa Koleva-Kolarova; James Buchanan
Published in: Applied Health Economics and Health Policy, 5, 2022, ISSN 1179-1896
Publisher: Springer
DOI: 10.1007/s40258-021-00714-9

Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine.

Author(s): Vellekoop, Heleen; Huygens, Simone; Versteegh, Matthijs; Szilberhorn, László; Zelei, Tamás; Nagy, Balázs; Koleva-Kolarova, Rositsa; Tsiachristas, Apostolos; Wordsworth, Sarah; Rutten-van Mölken, Maureen
Published in: Pharmacoeconomics, 1, 2021, ISSN 1179-2027
Publisher: Springer
DOI: 10.1007/s40273-021-01010-z

The Net Benefit of Personalized Medicine: A Systematic Literature Review and Regression Analysis

Author(s): Heleen Vellekoop, Matthijs Versteegh, Simone Huygens, Isaac Corro-Ramos, László Szilberhorn, Tamás Zelei, Balázs Nagy, Apostolos Tsiachristas, Rositsa Koleva-Kolarova, Sarah Wordsworth, Maureen Rutten-van Mölken
Published in: Value in Health, 2022, ISSN 1098-3015
Publisher: Blackwell Publishing Inc.
DOI: 10.1016/j.jval.2022.01.006

POSB75 What Is the Net Added Value of Personalised Medicine? A Systematic Literature Review

Author(s): Vellekoop, H; Huygens, S; Versteegh, M; Corro Ramos, I; Szilberhorn, L; Zelei, T; Nagy, B; Koleva-Kolarova, R; Tsiachristas, A; Wordsworth, S; Rutten-Van Mölken, M
Published in: Value in Health, 4, 2022, ISSN 1098-3015
Publisher: Blackwell Publishing Inc.
DOI: 10.1016/j.jval.2021.11.348